Rothe, Achim, Sasse, Stephanie, Topp, Max S., Eichenauer, Dennis A., Hummel, Horst, Reiners, Katrin S., Dietlein, Markus, Kuhnert, Georg, Kessler, Joerg, Buerkle, Carolin, Ravic, Miroslav, Knackmuss, Stefan, Marschner, Jens-Peter, von Strandmann, Elke Pogge, Borchmann, Peter and Engert, Andreas (2015). A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood, 125 (26). S. 4024 - 4032. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Full text not available from this repository.Abstract
AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via binding to CD16A as immune effector cells. In this phase 1 dose-escalation study, 28 patients with heavily pretreated relapsed or refractory Hodgkin lymphoma received AFM13 at doses of 0.01 to 7 mg/kg body weight. Primary objectives were safety and tolerability. Secondary objectives included pharmacokinetics, antitumor activity, and pharmacodynamics. Adverse events were generally mild to moderate. The maximum tolerated dose was not reached. Pharmacokinetics assessment revealed a half-life of up to 19 hours. Three of 26 evaluable patients achieved partial remission (11.5%) and 13 patients achieved stable disease (50%), with an overall disease control rate of 61.5%. AFM13 was also active in brentuximab vedotin-refractory patients. In 13 patients who received doses of >= 1.5 mg/kg AFM13, the overall response rate was 23% and the disease control rate was 77%. AFM13 treatment resulted in a significant NK-cell activation and a decrease of soluble CD30 in peripheral blood. In conclusion, AFM13 represents a well-tolerated, safe, and active targeted immunotherapy of Hodgkin lymphoma. A phase 2 study is currently planned to optimize the dosing schedule in order to further improve the therapeutic efficacy. This phase 1 study was registered at www.clinicaltrials.gov as #NCT01221571.
| Item Type: | Journal Article | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Creators: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| URN: | urn:nbn:de:hbz:38-400838 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DOI: | 10.1182/blood-2014-12-614636 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Journal or Publication Title: | Blood | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Volume: | 125 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number: | 26 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Page Range: | S. 4024 - 4032 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Date: | 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Publisher: | AMER SOC HEMATOLOGY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Place of Publication: | WASHINGTON | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ISSN: | 1528-0020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Language: | English | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Faculty: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Divisions: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Subjects: | no entry | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Uncontrolled Keywords: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| URI: | http://kups.ub.uni-koeln.de/id/eprint/40083 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
 |
View Item |